Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR 2: Percutaneous Stellate Ganglion Block as First Line Treatment in Electrical Storm
NCT07841080Phase 3Not yet recruiting
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Oct 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lidocaine and bupivacaine in Electrical Storm (ES), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Complete Suppression of treated ventricular arrhythmias (ATP/DC shock) at 3 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
lidocainebupivacaine
03
Conditions
Electrical Storm (ES)
Beyond the preview
Go deeper on NCT07841080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841080.